Cost Burden Analysis: To calculate the income burden faced in each state, we compared the average monthly out-of-pocket price of GLP-1 medications (pricing assumptions reflect a blended cash-pay range of approximately $150$450 per month, with $350 used as a common injectable reference point rather than a universal baseline) to each states per capita annual income
P2 had a drug loading of approximately 23%
DOI: Published online: October 24, 2024 1 Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Korea 2 Biomedical Research Institute, Pusan National University Hospital, Busan, Korea 3 Department of Biostatistics, Clinical Trial Center, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea Corresponding author: Bo Hyun Kim Department of Internal Medicine, Pusan National University School of Medicine, 49 Busandaehak-ro, Mulgeum-eup, Yangsan 50612, Korea E-mail: [email protected] Copyright 2025 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

"Use of GLP-1 [drugs] is rapidly expanding in this population, highlighting an important area for future research." More information The Mayo Clinic has more on GERD
This combination promotes sustainable fat loss while improving overall metabolic health
Academy of Nutrition and Dietetics